NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/31/2024
Back to search
Official data from USPTO
CUROGEN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
36
Latest update
12/31/2024
Trademark type
Word
Nice classes
5, 42
Filing date
11/17/2021
Registration date
12/31/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/31/2024
Last transaction
12/31/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
Drawing code
4
Owner type
99
Owner location
Gyeonggi-do, KR
Examiner
MOSCATI, JUSTIN
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
CUROGEN Technology Co., Ltd.
Representatives
Steven John Hultquist HULTQUIST, PLLC
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
pharmaceutical preparations for diagnosis; diagnostic agents for pharmaceutical use; pharmaceutical preparations for the prevention of autoimmune diseases; pharmaceutical preparations for the treatment of auto-immune diseases; monoclonal antibodies for medical purposes; polyclonal antibodies for medical purposes; compounds for treating cancer; biological preparations for the treatment of cancer; pharmaceutical preparations and substances for the prevention of cancer; chemical preparations for pharmaceutical purposes for the treatment of cancer or autoimmune diseases; immunoassay reagents for medical use; biological preparations for medical purposes for the treatment of cancer or autoimmune diseases; chemico-pharmaceutical preparations for the treatment of cancer or autoimmune diseases; preparations of microorganisms for medical purposes; pharmaceuticals for the treatment of cancer or autoimmune diseases; pharmaceutical compositions for the treatment of cancer or autoimmune diseases
Class 42
pharmaceutical drug development services; research on the subject of pharmaceuticals; pharmaceutical drug development services; medicine research; analysis and evaluation of medical product development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing information on medical research being testinginspectionresearch of medical products; evaluating of clinical trial progress; development of biologics; research of biologics; biological research and analysis; drug discovery services; conducting clinical trials for others; scientific research; clinical trials; biological laboratory services; laboratory research in the field of chemistry; laboratory analysis in the field of chemistry; research and development of new products for others; pharmaceutical research and development
Publications
History of USPTO decisions and trademark events.
36 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
12/31/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/12/2024
PUBO
PUBLISHED FOR OPPOSITION
11/12/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/23/2024
OTHE
CASE RETURNED TO EXAMINATION
10/04/2024
IUCN
NOTICE OF ALLOWANCE CANCELLED
10/04/2024
JURT
JURISDICTION RESTORED TO EXAMINING ATTORNEY
10/03/2024
PCBG
PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
10/03/2024
APET
ASSIGNED TO PETITION STAFF
09/30/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/11/2024
EX2G
SOU EXTENSION 2 GRANTED
09/11/2024
EXT2
SOU EXTENSION 2 FILED
09/11/2024
EEXT
SOU TEAS EXTENSION RECEIVED
09/11/2024
TPAD
TEAS PETITION TO AMEND BASIS RECEIVED
09/11/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/07/2024
EX1G
SOU EXTENSION 1 GRANTED
03/06/2024
EXT1
SOU EXTENSION 1 FILED
03/06/2024
EEXT
SOU TEAS EXTENSION RECEIVED
03/06/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
09/19/2023
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
08/06/2023
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
04/26/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/28/2023
PUBO
PUBLISHED FOR OPPOSITION
03/28/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/08/2023
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
01/31/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/17/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/12/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/12/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/12/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/29/2022
GNRT
NON-FINAL ACTION E-MAILED
08/29/2022
CNRT
NON-FINAL ACTION WRITTEN
08/29/2022
DOCK
ASSIGNED TO EXAMINER
08/29/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/23/2021
NWAP
NEW APPLICATION ENTERED
11/20/2021
Continuous trademark protection
Get notified about every new filing that threatens CUROGEN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.